Trials / Completed
CompletedNCT06213831
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
A Maximal Use Trial of Ruxolitinib Cream in Adult Participants With Prurigo Nodularis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib Cream 1.5% | Ruxolitinib Cream 1.5% |
Timeline
- Start date
- 2024-02-27
- Primary completion
- 2025-07-17
- Completion
- 2025-07-17
- First posted
- 2024-01-19
- Last updated
- 2025-08-13
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06213831. Inclusion in this directory is not an endorsement.